The focus of the group is to understand and find effective means to overcome drug resistance in cancers. Our approach is to use systems biology, i.e., integration of large and complex molecular & clinical data (big data) from cancer patients with computational methods and wet lab experiments, to identify efficient patient-specific therapeutic targets.
We are particularly interested in developing and applying machine learning based methods that enable integration of various types of molecular data (DNA, RNA, proteomics, etc.) to clinical information. All our research is done in a cross-disciplinary and collaborative setting with oncologists, pathologists, biochemists and geneticians.